Navigation Links
Menon Biosensors Accurately Detects Biological Pathogen in More Than 2,200 Samples
Date:12/19/2013

SAN DIEGO, Dec. 19, 2013 /PRNewswire/ -- Menon Biosensors, a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens, today announced that its nuclear magnetic resonance (NMR) technology successfully detected Yersinia pestis, also known as the plague, in more than 2,200 samples without any false positives or negatives.

In the studies conducted over a six year period, Menon Biosensors' platform technology was able to detect the presence of Yersinia pestis in water, air, blood, sputum, urine and stool. Concentrations were as low as from 1 colony-forming unit (CFU) per sample, with a limit of detection in the range of 1-100 CFU/mL and a dynamic range of 1-10^9 CFU/mL.  Analyzing low level samples required minimal preparation time, and including measurement was completed in less than one hour. Menon Biosensors is currently conducting validation studies at Scripps La Jolla in Clostridium difficile (C. difficile) and Mycobacterium tuberculosis complex (TB), with data expected in early 2014.

"Having reviewed the new diagnostic technology, process and assay data generated using Menon Biosensors' technology in identifying several well-known pathogens, I believe this technology provides a foundation to achieve a more facile, next-generation DNA diagnostic platform," said John Spinosa, M.D., Ph.D., pathologist at Scripps La Jolla. "Menon Biosensors' technology has significant implications in molecular biochemistry diagnostic applications for improving patient care and outcomes in an affordable and streamlined manner."

Added David Schlotterbeck, chairman of Menon Biosensors, "This data demonstrates that our technology can more accurately and rapidly detect a biological pathogen compared to currently available tests, and with higher sensitivity. With our upcoming data in C. difficile and TB, we plan to demonstrate that it can be easily and accurately applied to different pathogens with assays developed in less than six months."

Menon Biosensors' platform technology has been validated through multiple studies with the U.S. government's Biodefense Program. In these studies, conducted in more than 3,000 samples over a six year period, the technology demonstrated greater than 99 percent accuracy. The tests were conducted in the presence of interferants and near neighbors of the pathogens to be detected. 

By providing accurate results in less than one hour from the time a sample is collected, Menon Biosensors' platform technology allows medical professionals to quickly treat a pathogen with the appropriate and potentially life-saving therapeutic. Current diagnosis techniques for many pathogens require several hours to multiple days for accurate detection, depending on the pathogen, which limits treatment options early in the patient's care.

The platform technology is portable and available in both manual and continuous configurations.  Operating the portable system requires less than 10 watts of electricity, which enables operation off of a battery.  The system size is less than a cubic foot and weighs less than 10 pounds.  Reagents used in the assays are lyophilized, allowing them to be stored at room temperature for more than one year without jeopardizing the effectiveness of the test. 

About Menon Biosensors

Menon Biosensors is a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens. Menon Biosensors' microfluidics and NMR platform technology provides superior sensitivity and specificity and minimizes sample preparation, thereby providing best in class sample-to-answer pathogen detection.  The technology has been validated by respected third parties in more than 3,000 samples over six years.


'/>"/>
SOURCE Menon Biosensors
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biosensors Reports Financial Results for the Second Quarter and First Half of Fiscal Year 2014
2. Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2014
3. Biosensors Reports Financial Results for Fiscal Year 2013
4. Biosensors Completes Spectrum Dynamics Assets Acquisition
5. Biosensors to Acquire Assets of Spectrum Dynamics
6. Frost & Sullivan Acknowledges that PKCs Biosensors are Expected to Become the New Industry Standard in Pathogen Testing
7. Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2013
8. Biosensors Reports Strong Sales and Profitability in the First Quarter of Fiscal Year 2013
9. New Data Suggests Abbotts High Sensitive Troponin Test May Help Doctors More Accurately Diagnose Heart Attacks in Women
10. Study Demonstrates Glysure Systems Ability to Accurately Measure Blood Glucose Levels in the ICU
11. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s work in cellular ... of researchers and leaders from Sanford Health were selected to participate in the ... Impact ” and receive the 2016 Pontifical Key Innovation Award at the Vatican. ...
(Date:4/28/2016)... ... 2016 , ... CastCoverz!, America’s #1 trusted brand for cast ... waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! offers ... night, weatherproof and waterproof covers for most orthopedic devices, including but not limited ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... Standards Consortium (CDISC) announces today the open availability of a new CDISC ... and catalogs for registering clinical trials. This innovative standard will make it ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... and the Campaign for Tobacco-Free Kids, a leading force in the fight to ... federal, state and local policies that can help reduce tobacco use. The initiative ...
(Date:4/28/2016)... ... 28, 2016 , ... In 2011, TIME magazine named Herr the “Leader of ... technology that marries human physiology with electromechanics. He continues that work as Director of ... of BionX , a leader in the field of prosthetic devices. , After ...
Breaking Medicine News(10 mins):